Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus discusses real-world evidence on the company’s cell-based quadrivalent influenza vaccine (QIVc), which was published in the peer-reviewed medical journal “Vaccine”. The study shows the value of cell-based quadrivalent influenza vaccine in preventing influenza-related hospitalization in the U.S. 2017/18 season.
Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior management positions, including Global Medical Lead for Pfizer’s pediatric pneumococcal vaccine and Worldwide Medical Lead for Merck’s HPV vaccine and Cabinet Secretary for Delaware’s Health & Social Services. Dr. Sylvester is a preventive medicine expert with a passion for disease prevention and health promotion on a local, statewide, and global basis. He has focused his career on developing sound health policy, implementing innovative public health programs and accelerating vaccine use worldwide.